

PARTICULARS TO APPEAR ON THE OUTER PACKAGE – OUTER CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Profender 96 mg/24 mg spot-on solution

2. STATEMENT OF ACTIVE SUBSTANCES

Each 1.12 ml pipette contains:
24 mg emodepside, 96 mg praziquantel

3. PACKAGE SIZE

2 pipettes
4 pipettes
12 pipettes
20 pipettes
40 pipettes

4. TARGET SPECIES

For large cats

> 5 kg – 8 kg

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Spot-on use
For external use only.



7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Store in the original package in order to protect from moisture.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Vetoquinol SA

14. MARKETING AUTHORISATION NUMBERS

Vm 06462/5009

15. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS – BLISTER**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Profender > 5 - 8 kg

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

24 mg emodepside / 96 mg praziquantel

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Vetoquinol logo

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS – PIPETTE LABEL**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Profender > 5 - -8 kg

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1.12 ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Vetoquinol logo

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Profender 30 mg / 7.5 mg spot-on solution for small cats
Profender 60 mg / 15 mg spot-on solution for medium cats
Profender 96 mg / 24 mg spot-on solution for large cats

2. Composition

Active substances:

Each ml contains:
21.4 mg emodepside and 85.8 mg praziquantel.

Each dosing unit (pipette) contains:

	Volume	Emodepside	Praziquantel
Profender for small cats ($\geq 0.5 - 2.5$ kg)	0.35 ml	7.5 mg	30 mg
Profender for medium cats ($> 2.5 - 5$ kg)	0.70 ml	15 mg	60 mg
Profender for large cats ($> 5 - 8$ kg)	1.12 ml	24 mg	96 mg

Excipients:

Butylhydroxyanisole (E320)5.4 mg/ml

Clear yellow to brown solution.

3. Target species

Cats.

4. Indications for use

For cats suffering from, or at risk from, mixed parasitic infections caused by roundworms, tapeworms and lungworms of the following species:

Roundworms (nematodes)

Toxocara cati (mature adult, immature adult, L4 and L3)

Toxocara cati (L3 larvae) – treatment of queens during late pregnancy to prevent lactogenic transmission to the offspring

Toxascaris leonina (mature adult, immature adult and L4)

Ancylostoma tubaeforme (mature adult, immature adult and L4)

Tapeworms (cestodes)

Dipylidium caninum (mature adult and immature adult)

Taenia taeniaeformis (adult)

Echinococcus multilocularis (adult)

Lungworms

Aelurostrongylus abstrusus (adult)

5. Contraindications

Do not use in kittens under 8 weeks of age or weighing less than 0.5 kg.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

6. Special warnings

Special warnings:

Shampooing or immersion of the animal in water directly after treatment may reduce the efficacy of the veterinary medicinal product. Treated animals therefore should not be bathed until the solution has dried.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infection based on its epidemiological features, for each individual animal.

The possibility that other animals in the same household can be a source of re-infection with roundworms, tapeworms and lungworms should be considered, and these should be treated as necessary with an appropriate veterinary medicinal product.

Special precautions for safe use in the target species:

Apply only to the skin surface and on intact skin. Do not administer orally or parenterally.

Avoid the treated cat or other cats in the household licking the site of application while it is wet.

There is limited experience on the use of the veterinary medicinal product in sick and debilitated animals, thus the veterinary medicinal product should only be used based on a benefit-risk assessment for these animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Do not smoke, eat or drink during application.

Avoid direct contact with application area while it is wet. Keep children away from treated animals during that time.

Wash hands after use.

In case of accidental spillage onto skin, wash off immediately with soap and water.

If the veterinary medicinal product accidentally gets into eyes, they should be thoroughly flushed with plenty of water.

If skin or eye symptoms persist, or in case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Care should be taken not to allow children to have prolonged intensive contact (for example, by sleeping) with treated cats during the first 24 hours after application of the veterinary medicinal product.

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Other precautions:

The solvent in this product may stain certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

Emodepside is a substrate for P-glycoprotein. Co-treatment with other veterinary medicinal product that are P-glycoprotein substrates/inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones, erythromycin, prednisolone and cyclosporine) could give rise to pharmacokinetic drug interactions. The potential clinical consequences of such interactions have not been investigated.

Overdose:

Salivation, vomiting and trembling were observed occasionally when the veterinary medicinal product was administered at up to 10 times the recommended dose in adult cats and up to 5 times the recommended dose in kittens. These symptoms were thought to occur as a result of the cat licking the application site. The symptoms were completely reversible.

There is no known specific antidote.

Major incompatibilities:

None known.

7. Adverse events

Cats:

Very rare (< 1 animal / 10,000 animals treated, including isolated reports):	Neurological disorders ^{1,2,3} (ataxia ^{1,2,3} (incoordination) tremor ^{1,2,3}) Hypersalivation ³ , vomiting ³ , diarrhoea ³ Application site alopecia ² (hair loss), application site pruritus (itching), application site inflammation
--	--

	Behavioural disorders (hyperactivity, anxiety, vocalisation) Anorexia, lethargy
--	--

¹ Mild

² Transient

³ These effects are thought to occur as a result of the cat licking the application site immediately after treatment

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Spot-on use.

For external use only.

Dosage and treatment schedule

The recommended minimum doses are 3 mg emodepside / kg body weight and 12 mg praziquantel / kg body weight, equivalent to 0.14 ml of the veterinary medicinal product / kg body weight (bw).

Body weight of cat (kg)	Pipette size to be used	Volume (ml)	Emodepside (mg/kg bw)	Praziquantel (mg/kg bw)
≥0.5 - 2.5	Profender for small cats	0.35 (1 pipette)	3 - 15	12 - 60
>2.5 - 5	Profender for medium cats	0.70 (1 pipette)	3 - 6	12 - 24
>5 - 8	Profender for large cats	1.12 (1 pipette)	3 - 4.8	12 - 19.2
>8	Use an appropriate combination of pipettes			


For the treatment of roundworms and tapeworms a single administration per treatment is effective.

For the treatment of queens to prevent lactogenic transmission of *Toxocara cati* (L₃ larvae) to the offspring, a single administration per treatment approximately seven days prior to expected parturition is effective.


For the lungworm *Aelurostrongylus abstrusus*, two treatments administered two weeks apart are effective.

9. Advice on correct administration

Remove one pipette from package. Hold pipette in upright position, twist and pull off cap and use the opposite end of the cap to break the seal.



Part the fur on the cat's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze firmly several times to empty the contents directly onto the skin. Application on the base of the skull will minimise the ability of the cat to lick the veterinary medicinal product off. Apply only to the skin surface and on intact skin.



Underdosing could result in ineffective use and may favour resistance development

To ensure a correct dosage, body weight should be determined as accurately as possible. If animals are to be treated collectively, reasonably homogeneous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in the original package in order to protect from moisture.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

The veterinary medicinal product should not enter water courses as emodepside may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Profender 30 mg / 7.5 mg spot-on solution for small cats – Vm 06462/5011
Profender 60 mg / 15 mg spot-on solution for medium cats – Vm 06462/5010
Profender 96 mg / 24 mg spot-on solution for large cats – Vm 06462/5009

White polypropylene pipettes with caps in aluminium blisters

Blister packs in a cardboard box containing 2, 4, 12, 20 or 40 dose pipettes (0.35 ml each).

Blister packs in a cardboard box containing 2, 4, 12, 20, 40 or 80 dose pipettes (0.70 ml each).

Blister packs in a cardboard box containing 2, 4, 12, 20, or 40 dose pipettes (1.12 ml each).

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Vetoquinol SA
34 Rue de Chene Sainte-Anne
Magny-Vernois
70200 Lure
France

Manufacturer responsible for batch release:
KVP Pharma + Veterinär Produkte GmbH
Projensdorfer Str. 324
24106 Kiel
Germany

VETOQUINOL BIOWET Sp. z o.o.
Żwirowa 140
66-400 Gorzów Wlkp.,
Poland

17. Other information

POM-V

Gavin Hall
Approved: 12 January 2026